GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor.
GMP—good manufacturing practice
autologous
automation
bioreactor
mesenchymal stromal cells
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
12
2021
accepted:
14
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
In recent years mesenchymal stromal cells (MSCs) have received a great deal of interest for the treatment of major diseases, but clinical translation and market authorization have been slow. This has been due in part to a lack of standardization in cell manufacturing protocols, as well as a lack of biologically meaningful cell characterization tools and release assays. Cell production strategies to date have involved complex manual processing in an open environment which is costly, inefficient and poses risks of contamination. The NANT 001 bioreactor has been developed for the automated production of small to medium cell batches for autologous use. This is a closed, benchtop system which automatically performs several processes including cell seeding, media change, real-time monitoring of temperature, pH, cell confluence and cell detachment. Here we describe a validation of the bioreactor in an environment compliant with current good manufacturing practice (cGMP) to confirm its utility in replacing standardized manual processing. Stromal vascular fraction (SVF) was isolated from lipoaspirate material obtained from healthy donors. SVF cells were seeded in the bioreactor. Cell processing was performed automatically and cell harvesting was triggered by computerized analysis of images captured by a travelling microscope positioned beneath the cell culture flask. For comparison, the same protocol was performed in parallel using manual methods. Critical quality attributes (CQA) assessed for cells from each process included cell yield, viability, surface immunophenotype, differentiation propensity, microbial sterility and endotoxin contamination. Cell yields from the bioreactor cultures were comparable in the manual and automated cultures and viability was >90% for both. Expression of surface markers were consistent with standards for adipose-derived stromal cell (ASC) phenotype. ASCs expanded in both automated and manual processes were capable of adipogenic and osteogenic differentiation. Supernatants from all cultures tested negative for microbial and endotoxin contamination. Analysis of labor commitment indicated considerable economic advantage in the automated system in terms of operator, quality control, product release and management personnel. These data demonstrate that the NANT 001 bioreactor represents an effective option for small to medium scale, automated, closed expansion of ASCs from SVF and produces cell products with CQA equivalent to manual processes.
Identifiants
pubmed: 35356775
doi: 10.3389/fbioe.2022.834267
pii: 834267
pmc: PMC8959900
doi:
Types de publication
Journal Article
Langues
eng
Pagination
834267Informations de copyright
Copyright © 2022 Fitzgerald, Duffy, Cattaruzzi, Vitrani, Paulitti, Mazzarol, Mauro, Sfiligoj, Curcio, Jones, McInerney, Krawczyk, Kelly, Finnerty, McDonagh, McCabe, Duggan, Connolly, Shaw, Murphy and Barry.
Déclaration de conflit d'intérêts
GC, FV, AP, FM, PM, and AS were employed by VivaBioCell S.p.A. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Thorac Cardiovasc Surg. 2016 Dec;152(6):1582-1588.e2
pubmed: 27665225
Methods Mol Biol. 2020;2086:151-163
pubmed: 31707674
Cell Stem Cell. 2008 Oct 9;3(4):369-81
pubmed: 18940729
Cytotherapy. 2018 Mar;20(3):394-406
pubmed: 29287970
Cytotherapy. 2013 Jun;15(6):641-8
pubmed: 23570660
J Am Coll Cardiol. 2017 Feb 7;69(5):526-537
pubmed: 27856208
Biotechnol Adv. 2019 Jan - Feb;37(1):239-245
pubmed: 30543841
SLAS Technol. 2018 Aug;23(4):364-373
pubmed: 29481762
J Orthop Res. 2019 Jun;37(6):1229-1235
pubmed: 31081558
Mater Sci Eng C Mater Biol Appl. 2019 Mar;96:77-85
pubmed: 30606590
J Bone Joint Surg Am. 1994 Apr;76(4):579-92
pubmed: 8150826
Cell Transplant. 2013;22(11):1981-2000
pubmed: 23107560
Bone Marrow Transplant. 1995 Oct;16(4):557-64
pubmed: 8528172
Transfusion. 2018 Oct;58(10):2374-2382
pubmed: 30203447
Biotechnol J. 2017 May;12(5):
pubmed: 27996210
Cytotherapy. 2019 Mar;21(3):289-306
pubmed: 30528726